Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harmony Biosciences Holdings, Inc.

32.05
+0.12000.38%
Volume:13.24K
Turnover:425.77K
Market Cap:1.84B
PE:12.23
High:32.46
Open:32.27
Low:31.95
Close:31.93
Loading ...

Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why

Zacks
·
25 Feb

5 High Earnings Yield Value Stocks to Buy Amid Market Volatility

Zacks
·
24 Feb

Harmony Biosciences Holdings Inc expected to post earnings of 74 cents a share - Earnings Preview

Reuters
·
21 Feb

Mizuho Adjusts Price Target on Harmony Biosciences to $42 From $52, Keeps Outperform Rating

MT Newswires Live
·
20 Feb

Harmony Biosciences Holdings, Inc. : Deutsche Bank Cuts Target Price to $52 From $55

THOMSON REUTERS
·
20 Feb

Concerns Over Harmony Biosciences: FDA Setback, Patent Risks, and High-Risk Pipeline

TIPRANKS
·
20 Feb

Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

Benzinga
·
20 Feb

Harmony Biosciences Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

Harmony Biosciences: Buy Rating Affirmed Despite FDA Setback, Strong Growth Potential in Pitolisant Franchise and Pipeline Opportunities

TIPRANKS
·
20 Feb

BUZZ-Harmony Biosciences drops after FDA refuses to review hypersomnia drug

Reuters
·
20 Feb

Harmony Biosciences Is Maintained at Buy by Needham

Dow Jones
·
20 Feb

BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia

Reuters
·
19 Feb

Harmony Biosciences: FDA Turns Away Idiopathic Hypersomnia Application

Dow Jones
·
19 Feb

Harmony Biosciences : Needham Cuts Target Price to $50 From $52

THOMSON REUTERS
·
19 Feb

Harmony Biosciences Receives US FDA's Refusal to File Letter Related to Application for Pitolisant in Idiopathic Hypersomnia

MT Newswires Live
·
19 Feb

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

THOMSON REUTERS
·
19 Feb

Harmony Biosciences Holdings Inc - Receives FDA Refusal to File Letter for Pitolisant

THOMSON REUTERS
·
19 Feb

Harmony Biosciences -on Track to Initiate a Phase 3 Registrational Trial of Pitolisant Hd in Ih in Q4 2025, With a Target Pdufa Date in 2028

THOMSON REUTERS
·
19 Feb

Harmony Biosciences Holdings Inc - 2025 Net Revenue Guidance Remains Unchanged at $820-$860 Million

THOMSON REUTERS
·
19 Feb

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

Business Wire
·
19 Feb